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Abstract 19 
Visual hallucinations (VH) are a common symptom of Parkinson’s disease with dementia (PDD), 20 
affecting up to 65% of cases. Integrative models of their etiology posit that a decline in executive 21 
control of the visuo-perceptual system is a primary mechanism of VH generation. The role of 22 
bottom-up processing in the manifestation of VH in this condition is still not clear. Here we 23 
compared amplitude and latency patterns of reversal visual evoked potentials (VEPs) in healthy 24 
controls (n=21) and PDD patients (n = 34) with a range of VH severities. PDD patients showed 25 
increased N2 latency relative to controls, but patients reporting complex VH (n=17) did not 26 
demonstrate any relationship between VEP measurements and their hallucination severity as 27 
measured on the neuropsychiatric inventory hallucinations subscale (NPIHal) score. Our VEP 28 
findings support previous reports of declining visual system physiology in PDD. However, no 29 
notable major relationships between the integrity of the visual pathway and VH were found. 30 
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1 Introduction 31 
Visual symptoms are common in Parkinson’s disease (PD), and include double vision, dry or painful 32 
eyes, poor contrast sensitivity, problems with color vision, and blurring of vision or lowered acuity 33 
(Biousse et al., 2004; Davidsdottir et al., 2005; Archibald et al., 2009; Urwyler et al., 2014; Weil et 34 
al., 2016). Such problems have been linked to the physical decline of retinal function over the course 35 
of disease development with depletion of retinal dopamine (Nguyen-Legros, 1988), and retinal nerve 36 
fiber layer thinning (Lee et al., 2014). Electrophysiological measures of visual health, such as the 37 
visual evoked potential (VEP), and the electroretinogram (ERG), have been widely used to support 38 
the diagnosis of PD as indirect measures of health and integrity of early bottom-up visual processing 39 
pathways. Measurements of scalp potentials, as well as scotopic alpha and beta waves generated on 40 
the retina during foveal stimulation typically demonstrate a slowing of peak activity in PDD patients 41 
relative to controls (Bodis-Wollner and Yahr, 1978; Calzetti et al., 1990; Nowacka et al., 2015), 42 
acting as indirect support for pathological evidence of a decline in pre-geniculate visual function 43 
(Nguyen-Legros, 1988; Lee et al., 2014). 44 
In 45% of PD cases without dementia (Aarsland et al., 1999; Fénelon et al., 2000), and up to 65% of 45 
cases with dementia (PDD) (McKeith et al., 2005), patients will also experience visual hallucinations 46 
(VH). The early presence of VH is a strong predictor of cognitive decline (Aarsland et al., 2003), as 47 
well as increased mortality and overall reduced quality of life for patients and their carers (Goetz and 48 
Stebbins, 1993; 1995). Models of VH in Lewy body dementias (including dementia with Lewy 49 
bodies (DLB), and PDD) have posited that VH are a product of the inefficient integration of multiple 50 
perceptual sub-divisions of the visual system (Collerton et al., 2005; Shine et al., 2011). The 51 
framework for healthy visual perception involves the prediction of sensory inputs expected from the 52 
salient features of images (based upon long-term memory of similar images and current context) 53 
which are then matched to the actual sensory inputs to minimize any discrepancy between the two.  54 
Thus, perception needs to balance predictions and sensory information. Impairments in cognitive 55 
control across executive networks in PDD lead to difficulties balancing these processes, thus 56 
impairing the accuracy of matching the visual input to expectations. Despite the precise etiology of 57 
VH being unclear, variations in the frequency of visual hallucinations over the course of disease 58 
progression suggests that these hallucinations reflect a complex relationship between declining 59 
sensory function and dysfunctional predictions (Collerton et al., 2005; Onofrj et al., 2007; Fenelon, 60 
2008; Llebaria et al., 2010; Sanchez-Castaneda et al., 2010; Shine et al., 2011). 61 
In this investigation we sought to characterize the components of early bottom-up processing in PDD 62 
patients, using the pattern reversal visual evoked potential, and to relate the response features to the 63 
complexity of the VHs experienced. Based on available evidence of physiological decline in PDD we 64 
predicted that we would observe a general reduction in the amplitude of the VEP components, as 65 
well as an increase in the P1 latency (Matsui et al., 2005). In addition we expected baseline visual 66 
acuity and visual perception, to demonstrate a decline in those with a more severe and frequent 67 
complex  VH. This should also extend to an association between VEP P1 and N2 measurements with 68 
VH experience, as both of these are thought to be contingent upon attentional and perceptual 69 
processes (Haider et al., 1964; Luck 2005), which are, in particular, disrupted by Lewy body 70 
pathology (Shine et al., 2011; Taylor et al., 2011). 71 
2 Methods 72 
2.1 Participants 73 
 . CC-BY-NC-ND 4.0 International licenseIt is made available under a 
 is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)
The copyright holder for this preprint this version posted June 29, 2020. ; https://doi.org/10.1101/2020.06.28.20142042doi: medRxiv preprint 
Bottom-Up Visual Processing and Visual Hallucinations in PDD 
 
3 
A total of 21 healthy controls, and 38 Parkinson’s disease with dementia (PDD) patients were 74 
recruited from the North East of England. Ethical approval was granted by the Newcastle National 75 
Health Service (NHS) Health Research Authority (HRA) (REC reference: 13/NE/0252; R&D 76 
reference: 6691). The diagnosis of PDD was confirmed by two independent and experienced 77 
clinicians (Charlotte Allan, John-Paul Taylor) and met with the standards described in the 78 
international PD diagnostic criteria (Emre et al., 2007). Participants were excluded from the study if 79 
baseline assessment revealed the presence of comorbid factors including stroke, non-PD related 80 
dementia, and/or visual dysfunction secondary to glaucoma. All procedures related to the study were 81 
explained to the participants and written informed consent was obtained prior to participation.  82 
2.2 Clinical assessments 83 
All participants were assessed on their level of global cognitive function using the Mini Mental State 84 
Exam, (MMSE, (Folstein et al., 1975); maximum score of 30) and the Cambridge Cognitive Test 85 
Battery (CAMCOG total score, (Roth et al., 1986; Roth et al., 1988); maximum score of 107). Motor 86 
function was assessed using the total (left and right) score from the Unified Parkinson’s disease 87 
rating scale section three (UPDRS-III, (Fahn et al. 1987); maximum score of 57).  88 
The integrity of the participant’s visual acuity was assessed using a detailed screening questionnaire,  89 
computerized Freiburg acuity testing (Bach, 1996), and the LOGMAR (Logarithm of the Minimum 90 
Angle of Resolution) scale of visual acuity. Visuo-perceptual function was assessed using 91 
performance on motion sensitivity, (Wood et al., 2013), angle discrimination (Wood et al., 2013), 92 
and performance on the pareidolic imagery test (Uchiyama et al., 2012).  93 
2.3 Visual Hallucinations 94 
The hallucination subscale of the Neuropsychiatric Inventory (NPIHal) (Cummings et al., 1994) was 95 
used for assessing VH occurring in the previous month, with the NPIHal score (frequency × severity 96 
of hallucinations) derived as a measure. For reliability, patients and carers were independently asked 97 
about the occurrence of VH in the month before using the North-East Visual Hallucinations 98 
Interview (NEVHI) (Mosimann et al., 2008). Any discrepancies in the reporting of VH (Urwyler et 99 
al., 2015) were discussed with both parties and the assessor, with reformulation of NPIHal scores 100 
(wherever the patient seemed to lack insight, primacy was given to caregiver opinion). 101 
Participants were classed as active visual hallucinators (PD-VH, n=17) if they had complex VH in 102 
the month preceding their interview; otherwise, they were classed as non-hallucinators (controls 103 
(n=21) and PD-NVH(n=17)). Participants with minor VH (e.g., passage or feeling of presence) but 104 
no complex VH in the last month were included in the PD-NVH group. This distinction was made 105 
due to the different etiologic basis to complex VH even though minor VH typically precede complex 106 
VH. Patients in this study map onto the same categories used in previously published research from 107 
our lab (see Firbank et al., 2018). 108 
2.4 EEG 109 
2.4.1 Visual Evoked Potential Presentation and Recording 110 
The VEP adhered to the specifications proposed by the International Society for Clinical 111 
Electrophysiology of Vision (Odom et al., 2010) (ISCEV). Participants viewed a black and white 112 
checkerboard pattern whilst the checks (visual angle of 0.6˚) reversed phase at a rate of 1Hz 113 
(switching to the opposite phase every 500ms), for 200 sweeps, with a brief rest period (3000ms) 114 
after 100 sweeps.  During stimulus presentation a pink dot was placed in the center of the display as a 115 
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focus point, which the participant was instructed to look at. This was intended to prevent wandering 116 
gaze during the check reversal and was presented on top of a grey background during the rest period. 117 
The stimulus was generated on a Dell OptiPlex 755 (Microsoft Windows XP) using Matlab v2012a 118 
(The MathWorks, 2012), and presented using a Dell U2412M 24-inch LCD monitor (resolution: 119 
1920 x 1200 pixels refresh rate: 60Hz). Pattern reversal visual evoked potentials were recorded 120 
during three separate viewing conditions (both eyes, left eye, right eye), using an ASA-LAB 136 121 
system amplifier and the ASA-LAB recording software (version 4.9.1) in combination with a 128 122 
Ag/AgCl channel Waveguard cap (10-5 system, (Oostenveld and Praamstra, 2001) Advanced Neuro 123 
Technologies). The ground electrode was placed on the right clavicle, and Fz was used as the 124 
reference electrode. Electrode impedance was kept below 5kΩ, and no filters were applied during the 125 
acquisition of EEG data. 126 
2.4.2 Pre-Processing 127 
Signal processing and measurement was performed using Matlab v2012a (The MathWorks, 2012), 128 
with the EEGLab (Delorme and Makeig, 2004), ERPLab (Lopez-Calderon and Luck, 2014), and 129 
current source density (Kayser and Tenke, 2006) (CSD) toolboxes. Individual sweeps were split into 130 
epochs of 400ms, a baseline period of 100ms prior to stimulus presentation, and a post-stimulus 131 
period of 300ms. Epochs were baseline corrected using the mean of the data in the pre-stimulus 132 
period and filtered using a 0.1 to 45Hz bandpass filter. Individual channels with a kurtosis value 133 
greater than three standard deviations from the cap-wide mean were removed and recreated after pre-134 
processing using spherical interpolation (Perrin et al., 1989; Ferree, 2000; Delorme and Makeig, 135 
2004; Ferree, 2006). After removing trials containing blinks, muscular activity, and drifting 136 
potentials (impedance related artefacts), broad spatial effects of the electric field were attenuated by 137 
applying a Laplacian transform (Kayser and Tenke, 2006). This approach was applied to reduce the 138 
likelihood of false positives in spatially distant locations when defining the occipital region of 139 
interest (ROI). 140 
2.4.3 Measurement 141 
To account for individual variance in the timing of synaptic communication the VEP components 142 
were measured within windows defined by the global field power (GFP) for each individual. The 143 
VEP components elicited three GFP maxima following stimulus presentation, each of which was 144 
used as the center point for the corresponding component window (GFP maxima ±10ms).  The 145 
occipital ROI was defined by measuring the amplitudes of the P1 component for the grand average of 146 
the control data set and using the 20 electrodes with the greatest amplitude as the limit for the ROI. 147 
Individual subject measurements of peak latency and mean amplitude were taken from the average 148 
VEP waveform within the occipital ROI. To account for potential inter-ocular latency differences we 149 
estimated the difference between P1 peak latency measurements for the left and right eyes.  150 
2.4.4 Statistical Analysis 151 
All statistical tests were performed using the Statistical Package for the Social Sciences (SPSS, 152 
version 22). Demographic and baseline factors were compared using independent samples t-tests. We 153 
compared the measurements of amplitude and latency separately for each component using univariate 154 
analysis of variance controlling for age and inter-ocular latency difference between the left and right 155 
eyes. Effect sizes were estimated using the partial eta squared measure (η2). To explore the 156 
relationship between the variance within our physiological measurements and VH experience in the 157 
hallucinating PDD group, we performed Spearman’s correlations between each VEP measurement 158 
and NPI hallucination subset score. To help identify any variance in our measurements accounted for 159 
by clinical and/or demographic factors we performed additional Spearman’s correlations between the 160 
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VEP measurements and each value. Significance for all tests was determined using an alpha criterion 161 
of p<0.05, and Bonferroni corrected for multiple comparisons (corrected alpha criterion of p<0.016). 162 
Where appropriate un-corrected correlations are reported to highlight trends within individual results. 163 
3 Results  164 
3.1 Demographics & Clinical Scores 165 
Demographic results are summarized in Table 1. All groups were matched for age and there were no 166 
significant differences in duration of PD or levodopa dose between the PDD-VH and PDD-NVH 167 
groups. PDD patients displayed a significant reduction in global cognitive function, UPDRS motor 168 
score relative to controls, with the PDD-VH group global cognitive function and motor function were 169 
significantly worse when compared to the PDD-NVH group.  170 
3.2 Visual Integrity & Visual Perceptual Scores 171 
Visual acuity and perceptual scores are summarized in Table 1. There was a pattern of overall decline 172 
in visual integrity within the PDD patients relative to the control group, characterized by a significant 173 
reduction in decimal and LOGMAR measurements of visual acuity. As expected, PDD-VH patients 174 
showed a characteristic significant increase in the number of false perceptions reported during the 175 
pareidolia task compared to PDD-NVH patients.  176 
[Table 1 Here] 177 
3.3 Visual Evoked Potential 178 
Amplitude tended to be smaller, and latency later in PDD vs controls, although this was not 179 
significant, except for N2. There were no significant differences between PDD-VH vs PDD-NVH. 180 
(see Table 2). Follow up simple effects analysis demonstrated that N2 latency in controls was 181 
significantly less than PDD-VH (p = .022) and PDD-NVH group (p = .03), but the N2 latency did not 182 
differ between the VH and NVH group. 183 
[Table 2 Here] 184 
3.4 Clinical Correlations 185 
Visual hallucination experience, as measured using the NPIHal subscale was not significantly related 186 
to the measurements of any of the VEP components. In PDD-VH patients there were no significant 187 
correlations between any of the VEP measurements, demographic, and clinical factors. 188 
4 Discussion 189 
In healthy participants, the VEP reflects a combination of many pre-striate and cortical processes. It 190 
is noted that a decline in visual pathway integrity following structural changes to the retina can affect 191 
the latency and amplitude (Bodis-Wollner and Onofrj, 1982; Bhaskar et al., 1986; Nowacka et al., 192 
2015; Miri et al., 2016).  In earlier studies the VEP has consistently been shown to be affected by PD 193 
neuropathology, indicating substantial decline in the quality of bottom-up visual processing 194 
(Archibald et al., 2009; Bodis-Wollner & Yahr, 1978; Nowacka et al., 2015).  Following the 195 
hypothesis that disrupted bottom-up processing of visual input is associated with the generation of 196 
VH in PDD we investigated whether the VEP could be used as a marker of hallucination 197 
symptomology. 198 
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In accordance with previous research (Mosimann et al., 2004; Emre et al., 2007; Archibald et al., 199 
2009; Possin, 2010; Landy et al., 2015) the PDD patients demonstrated a reduction in visual acuity, 200 
impaired visual perception, impoverished motor ability, and compromised global cognition. Analysis 201 
of the pattern reversal VEP data revealed a significant increase in the PDD N2 latency relative to 202 
controls, especially in PDD-VH, and non-significant reduction in the PDD P1 amplitude. P1 and N2 203 
(N140) are both linked to physical properties of the stimulus such as luminance, brightness, position 204 
on the retina, and associated attentional demands (Van Voorhis and Hillyard, 1977; Hillyard and 205 
Munte, 1984; Luck et al., 1994; Johannes et al., 1995; Ito and Gilbert, 1999; Johannes et al., 2003). 206 
Further, the N2 (N140) has been reported to be associated with increased disease severity (Talebi et 207 
al, 2014). In patients with PDD there are often abnormalities associated with the structure and 208 
function of the retina, including changes in morphology and dopaminergic signaling (Archibald et al., 209 
2009), which have previously been linked to reduced conduction velocity in early visual processing 210 
(Regan and Neima, 1984; Bodis-Wollner et al., 1987; Jones et al., 1992; Price et al., 1992; Pieri et 211 
al., 2000; Holroyd et al., 2001; Nowacka et al., 2015). Source localization of these components 212 
places the generating sources deep within the secondary visual cortex (Di Russo et al., 2002; Di 213 
Russo et al., 2005); although their cognitive associations suggest that their activity is governed as 214 
part of a higher order visual processing network. Given the lack of association between the VEP 215 
components and clinical measurements in our study it is unclear what relationship exists between the 216 
primary visual cortex and its bottom-up and top-down inputs in this context. However, our 217 
experimental design is limited in the scope to which we can draw conclusions on the nature of 218 
pathological change within the executive system and the link between attention and passive 219 
perception of the VEP stimulus.  220 
In the context of a mechanism for VH, our sample results suggest that bottom-up processing is not 221 
differentially affected between hallucinators and non-hallucinators. This is not unexpected as it 222 
follows that in an integrative model of VH we would expect VH content to stem from the interaction 223 
of impaired bottom-up processing with dysfunctional top-down control of perception. In our data, 224 
complex VH were associated with greater decline in CAMCOG, and UPDRS scores, as well as 225 
increased numbers of pareidolia relative to patients without complex VH. The divergence in the 226 
cognitive and perceptual profile of the groups supports a deteriorated capacity for effective top-down 227 
control, which in this model would be a pre-requisite factor for the generation of complex VH.  228 
However, these measures were not significantly correlated with the amplitude or latency of the VEP 229 
component measurements suggesting that conduction velocity and basic processing of visual feature 230 
information is unimpeded by the integrity of detailed perceptual processing. 231 
Within the integrative model of complex VH in Lewy body dementias the importance of bottom-up 232 
processing is thought to be its influence on the generation of proto-objects (Collerton et al., 2005; 233 
Shine et al., 2011). The frequency and phenomenology of the VH would then depend on the 234 
interaction between the executive system and the perceptual processing centers. Therefore, declining 235 
visual health and perceptual quality might simply place the individual in an at-risk state for VH 236 
development (Firbank et al., 2018) rather than directly impact their generation. Further research is 237 
required to model the way pathological effects on top-down processing interact with declining visual 238 
health. 239 
4.1 Limitations  240 
There are several limitations. Firstly, the sample size within this study was relatively small. 241 
Secondly, we used only a single subjective measure for VH severity. The NPI items are typically 242 
collected from the carers of the patient, and do not ask questions about the content of the 243 
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hallucination. It thus remains possible that there could be a relationship between visual health, 244 
bottom-up processing, and VH content that could be accessed by quantifying a scale such as the 245 
North East Visual Hallucination Interview (NEVHI) (Mosimann et al., 2008). Furthermore, the range 246 
of VH severity scores in our groups was limited making correlative analyses more difficult.   247 
4.2 Conclusion 248 
In summary, PDD patients demonstrated a diminished profile for visual information processing by 249 
way of lowered acuity and reduced visual integrity. This was partially reflected in the outcome of the 250 
VEP components, although the broad lack of significant differences between PDD-VH, PDD-NVH, 251 
and healthy controls implies that bottom-up visual information processing remains reasonably intact. 252 
Our findings support a separation between bottom-up information processing and the mechanism of 253 
complex VH generation, and instead imply that the reduced visual integrity might act to place the 254 
individual in an at risk state for the development of hallucinations in patients with a deteriorated 255 
cognitive profile. Future work should focus on a multimodal approach to understanding the 256 
interactions between top-down and bottom-up perceptual circuitry and how this is impacted by PDD 257 
neuropathology.   258 
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10 Figure Captions 278 
Table 1 | Participant demographics and clinical scores. Data are mean ± standard deviation. Statistical 279 
tests: : Univariate analysis of variance (ANOVA), p–value 2 sided <0.05 significant; PD = 280 
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Parkinson’s disease, PDD = Parkinson’s disease dementia, MMSE = Mini-Mental State Examination, 281 
CAMCOG = Cambridge Cognitive Assessment, UPDRS = Unified Parkinson’s Disease Rating 282 
Scale, HC = Healthy Controls, VH = Visual Hallucination, NVH= No Visual Hallucination; Tests 283 
reported used univariate ANOVA with partial eta squared effect size, except for Levodopa, age at 284 
onset, duration of PD, and NPI Hal total which used independent samples t-tests and Cohen’s D 285 
effect sizes.  286 
Table 2 | Comparison of the visual evoked potential component (N1, P1 and N2) amplitude and 287 
latency. Data are mean ± standard deviation. Statistical tests: Univariate analysis of variance 288 
(ANOVA), df=52, p–value 2 sided <0.05 significant; PDD = Parkinson’s disease dementia; HC = 289 
Healthy Controls; VH = Visual Hallucination; NVH= No Visual Hallucination; * Posthoc = VH>HC, 290 
NVH>HC;   291 
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Table 1, Participant demographics and clinical scores. *Denotes significant at p<0.05 474 
Measurement  
Controls PDD NVH PDD VH 
Posthoc 
Statistics 
(n=21) (n=17) (n=17) Test Val, p, Effect Size 
Age (years) 74.90 ± 5.16 72.94 ± 5.19 73.88 ± 5.36 
 
0.756, 0.524, 0.026 
MMSE score* 29.10 ± 1.81 24.59 ± 5.0 22.76 ± 4.99 HC>VH, HC>NVH 12.307, <0.001, 0.321 
CAMCOG total score* 95.14 ± 6.79 80.94 ± 15.53 73.18 ± 15.91 
HC>VH, HC>NVH, 
VH<NVH 
14.003, <0.001, 0.350 
CAMCOG Memory score* 23.52 ± 1.5 19.94 ± 4.93 17 ± 4.1 HC>VH, HC>NVH 15.32, <0.001, .36 
CAMCOG Executive score* 22.28 ± 3.16 14.53 ± 3.93 12.44 ± 4.04 HC>VH, HC>NVH 38.67, <.001, .59 
UPDRS III score* 2.10 ± 2.47 38.65 ± 21.93 57.88 ± 20.47 
HC<VH, HC<NVH, 
VH>NVH 
55.147, <0.001, 0.680 
Acuity (decimal)* 0.58 ± 0.31 0.29 ± 0.21 0.31 ± 0.19 HC>VH, HC>NVH 7.783,  0.01, 0.234 
Acuity (logmar)* 0.31 ± 0.26 0.65 ± 0.32 0.57 ± 0.27 HC>VH, HC>NVH 7.823,  0.001, 0.235 
Minimum Angle Perception 
(degrees)* 
8.63 ± 3.25 28.42 ± 23.51 32.68 ± 30.07 HC<VH 7.059,  0.002, 0.214  
Motion Perception* -2.72 ± 0.72 1.80 ± 3.15 2.68 ± 2.88 HC<VH 26.746,  <0.001, 0.522 
Number of Pareidolia* 1.0 ± 1.46 3.18 ± 4.54 6.82 ± 5.58 HC<VH, VH>NVH 8.188,  0.001, 0.254 
Levodopa Dose (24 hours, mg)   569.12 ± 303.05 710.59 ± 363.10 
 
-1.04, 0.31, 0.35 
Age at Onset of PD symptoms 
(years) 
  64.65 ± 7.08 60.88 ± 7.62 
 
1.06, 0.29, 0.36 
PD Duration (years)   7.18 ± 4.51 10.82 ± 7.46  -1.47, 0.15, 0.5 
NPI total score*   0.29 ± 0.58 3.11 ± 2.05 NVH<VH -5.44, <.001, 3.23 
      
            
Data are mean ± standard deviation. Statistical tests: : Univariate analysis of variance (ANOVA), p–value 2 sided <0.05 significant; PD = Parkinson’s disease, PDD = 475 
Parkinson’s disease dementia, MMSE = Mini-Mental State Examination, CAMCOG = Cambridge Cognitive Assessment, UPDRS = Unified Parkinson’s Disease Rating 476 
Scale, HC = Healthy Controls, VH = Visual Hallucination, NVH= No Visual Hallucination; Tests reported used univariate ANOVA with partial eta squared effect size, 477 
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Table 2, Comparison of the visual evoked potential component (N1, P1 and N2) amplitude and latency  482 
 483 







F, p-value, η2  
N1 Amplitude 
(µv) 
-1.27 ± 0.93 -0.85 ± 0.82 -0.84 ± 0.51 1.63, 0.21, 0.06 
Latency 88.28 ± 8.62 90.23 ± 08.68 93.35 ± 10.47 0.46, 0.63, 0.02 
      
P1 Amplitude 
(µv) 





127.59 ± 7.73 126.84 ± 6.33 1.47, 0.24, 0.06 
      
N2 









7.44, 0.001*, 0.23 
Data are mean ± standard deviation. Statistical tests: Univariate analysis of variance (ANOVA), df=52, p–value 2 sided <0.05 significant; PDD = Parkinson’s disease 484 
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